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Background
Kaposi’s sarcoma herpesvirus (KSHV) is the etiological
agent of Kaposi’s sarcoma (KS). Understanding the
interplay of viral and host factors in KS carcinogenesis
is critical for the rational development of new therapies.
Reactive oxygen species (ROS) have a recognized broad
function in oncogenesis mediated by signaling cascades
leading to the Rac1 activation of NADPH oxidases
(Nox) [1]. ROS play a role in cell cycle regulation and
angiogenesis, yet the specific molecular events linking
ROS and these cancer hallmarks are still elusive. KSHV
encodes a constitutively active G protein-coupled recep-
tor (vGPCR) [2], which triggers KS-like sarcomagenesis
via Rac1 [3]. It has been shown that Rac1-activated
mutant induces tumors resembling Kaposi’s sarcoma by
a ROS-mediated mechanism in transgenic mice [4,5].
Moreover, Rac1 is overexpressed in AIDS-KS lesions
and in KSHV-infected mECK36 tumors, pointing to a
role for KSHV-induced Rac1-mediated production of
ROS in KS pathogenesis [5]. The current study explored
the induction of oxidative stress pathways in the KSHV-
induced mouse model mECK36.
Results
vGPCR expression led to the upregulation of the c-sis/
PDGFB oncogene in a dose-dependent manner in
mECK36. PDGFB upregulation was dependent on Rac1
and ROS since it was suppressed by the Rac1 inhibitor
EHT1864 and the ROS scavenger N-acetyl cysteine
(NAC). PDGF activated oxidative signaling in a Rac/
Nox/ROS-dependent manner in latently infected cells,
leading to the upregulation of important genes for pro-
liferation and angiogenesis, such as c-Myc and VEGFA
through the activation of the STAT3 transcription
factor. Treatment with antioxidant NAC and PDGF
receptor inhibitors (imatinib and sunitinib) proved effec-
tive in inhibiting KSHV-induced tumorigenesis in the
mECK36 mouse model.
Conclusions
Our results show a novel KSHV-driven oncogenic
mechanism mediated by PDGF-B, whereby KSHV infec-
tion induces and exploits ROS production. ROS can be
targeted therapeutically by using the NAC antioxidant
or FDA-approved PDGF receptors inhibitors. Imatinib
clinical responses in AIDS-KS could be due to PDGF-
receptor inhibition of ROS production and warrant
further clinical trials and molecular exploration of these
new molecular therapeutic and prevention targets in
AIDS-KS.
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